

Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience

Authors

Marika Porrazzo,¹ Tiziana Moscato,² Giuseppe Sapienza,³ Fabrizio Accardi,¹ Caterina Patti,¹ Clotilde Cangialosi,¹ Carmelo Costanza,¹ Roberto Bono,³ Stefania Tringali,³ Cristina Rotolo,³ Emilia Gigliotta,⁴ Andrea Rizzuto,⁴ Manuela Giuseppa Ingrasci,⁴ Giulia Butera,⁴ Laura Di Noto,⁵ Alessandra Santoro,⁶ Anna Marfia,⁶ Cirino Botta,⁴ Sergio Siragusa,⁴ Massimo Martino² and Luca Castagna³

¹Onco-Hematology Unit, Azienda Ospedaliera Riunita (AOR) Villa Sofia-Vincenzo Cervello, Palermo; ²Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria; ³BMT Unit, Azienda Ospedaliera Riunita (AOR) Villa Sofia-Vincenzo Cervello, Palermo; ⁴Department of Health Promotion, Mother and Child Care, Internal

Medicine and Medical Specialties University of Palermo, Palermo; ⁵Transfusional and Transplantation Unit, Azienda Ospedaliera Riunita (AOR) Villa Sofia-Vincenzo Cervello, Palermo and ⁶Onco-Hematology and Cell Manipulation Laboratory Unit, Azienda Ospedaliera Riunita (AOR) Villa Sofia-Vincenzo Cervello, Palermo, Italy

Correspondence:
L. CASTAGNA - l.castagna@villasofia.it

<https://doi.org/10.3324/haematol.2024.286332>
Received: July 24, 2024.
Accepted: October 22, 2024.
Early view: October 31, 2024.

©2025 Ferrata Storti Foundation
Published under a CC BY-NC license 

	N= 99
Age, yr, median (range)	60,5 (42-71)
PAM dose	
140 mg/m ²	34
200 mg/m ²	66
Median number CD34+ infused (x10 ⁶ /kg)	4 (2-7.8)
Median time to ANC > 0.5 (x10 ⁹ /L)	11 days (6-24)
Median time to PLT > 20 (x10 ⁹ /L)	14 days (7-35)

Supplementary Table 1. Transplant characteristics.

ANC: absolute neutrophil count; PAM: melphalan; PLT: platelets

	N Dara	Induction	Mobilization strategy	Mobilization scheme	Plerixafor	CD34 collection target	CD34 trigger	CD34 peak	CD34 yield LK1	N CD34+ overall	Pts harvesting >4x10 ⁶ /kg	Plerixafor use	Mobilization failure
Thurlapati A et al. ¹⁰	43	Dara-VRD	Chemo-free	G-CSF + Plerixafor	Pre-emptive	≥2.5x10 ⁶ /kg ≥5x10 ⁶ /kg	NR	43 µL	4.9x10 ⁶ /kg	6.54 x10 ⁶ /kg	/	51%	No
Papaiakovou E et al. ¹⁴	40	Dara-VRD/VCD/VTD/KRD	Chemo-based	Cy 2.5 g/m ² + G-CSF	On demand	/	/	/	/	10.4 x10 ⁶ /kg	/	42%	/
Sauer S et al. ¹¹	68	Dara-VTD	Chemo-based	CAD or Cy + G-CSF	On demand	≥6x10 ⁶ /kg	10 µL	65 µL	5.5x10 ⁶ /kg	8.4 x10 ⁶ /kg	/	33%	No
Mina R et al. ¹⁵	10	Dara-VTD	Chemo-based	Cy 2-4 g/m ² + G-CSF	On demand	≥2x10 ⁶ /kg	20 µL	60 µL	9.9x10 ⁶ /kg	9.9x10 ⁶ /kg	95%	13%	4%
Zappaterra A et al. ¹²	20	Dara-VTD	Chemo-based	Cy 2-3 g/m ² + G-CSF	On demand	≥6x10 ⁶ /kg	20 µL	38 µL	3.9x10 ⁶ /kg	3.9 x10 ⁶ /kg	/	20%	NR
Liberatore C et al. ¹³	47	Dara-VTD	Chemo-based	Cy 4 g/m ²	On demand	≥6x10 ⁶ /kg	NR	NR	6.9x10 ⁶ /kg	10.6 x10 ⁶ /kg	/	49%	7%
This study	100	Dara-VTD	Chemo-free	G-CSF	On demand	≥6x10 ⁶ /kg	20 µL	58 µL	6.2x10 ⁶ /kg	6.2x10 ⁶ /kg	86%	36%	10%

Supplementary Table 2. PBSC mobilization/collection parameters reported in “real life” studies compared with our study.

§ in this study, plerixafor was used in front-line and 51% means that patients needed of 2nd administration.

CAD: cyclophosphamide, adriamycin, dexamethasone; Cy: cyclophosphamide; Dara-VRD: daratumumab, bortezomib, lenalidomide, dexamethasone; Dara-VTD: daratumumab, bortezomib, thalidomide, dexamethasone; G-CSF: granulocyte colony stimulating factor; KRD: carfilzomib, lenalidomide, dexamethasone; VCD: bortezomib, cyclophosphamide, dexamethasone; VTD: bortezomib, thalidomide, dexamethasone.